Perspectives of health care professionals on cancer cachexia: results from three global surveys
Perspectives of health care professionals on cancer cachexia: results from three global surveys
复制标题
DOI：
10.1093/annonc/mdw420
复制
发表时间：
2016-12-01
影响因子：
50.5
通讯作者：
Molfino, A.
中科院分区：
文献类型：
--
作者：
Muscaritoli, M.;Fanelli, F. Rossi;Molfino, A.
背景：恶病质在癌症患者中发病率高，并对预后、生活质量（QOL）和对治疗的耐受性/反应产生负面影响。本研究报告了三项调查的结果，旨在深入了解卫生保健专业人员（HCPs）对癌症恶病质（CC）的认识、理解和治疗实践。方法：在全球范围内对参与CC管理的医护人员进行调查。评估的主题包括CC的定义和同义词、诊断和治疗实践、CC治疗的目标和期望的改进。结果：共有来自14个不同国家的742名医护人员参与了调查。大多数（97%）的参与者是医学肿瘤学家或血液学家。CC最常被定义为体重减轻（86%）和食欲减退（46%）。体重减轻和食欲下降（分别为51%和34%）通常被视为CC的同义词。几乎一半（46%）的参与者报告说，如果患者体重减轻10%，就诊断为CC并开始治疗。然而，48%的参与者会等到体重减轻>= 15%才诊断出CC并开始治疗。HCPs还报告说，61%-77%的癌症患者在疾病达到第四阶段之前没有接受任何处方药物治疗。促进体重增加的能力被认为是选择CC治疗的最重要因素。治疗的主要目标包括确保患者能够应对癌症和治疗，并获得生活质量的改善。HCPs表达了对具有更多cc特异性作用模式的治疗和提高生活质量的治疗的渴望。结论：这些调查强调需要提高医护人员对CC及其管理的认识。
Background: Cachexia has a high prevalence in cancer patients and negatively impacts prognosis, quality of life (QOL), and tolerance/response to treatments. This study reports the results of three surveys designed to gain insights into cancer cachexia (CC) awareness, understanding, and treatment practices among health care professionals (HCPs).Methods: Surveys were conducted globally among HCPs involved in CC management. Topics evaluated included definitions and synonyms of CC, diagnosis and treatment practices, and goals and desired improvements of CC treatment.Results: In total, 742 HCPs from 14 different countries participated in the surveys. The majority (97%) of participants were medical oncologists or hematologists. CC was most frequently defined as weight loss (86%) and loss of appetite (46%). The terms loss of weight and decreased appetite (51% and 34%, respectively) were often provided as synonyms of CC. Almost half (46%) of the participants reported diagnosing CC and beginning treatment if a patient experienced a weight loss of 10%. However, 48% of the participants would wait until weight loss was >= 15% to diagnose CC and start treatment. HCPs also reported that 61%-77% of cancer patients do not receive any prescription medication for CC before Stage IV of disease is reached. Ability to promote weight gain was rated as the most important factor for selecting CC treatment. Key goals of treatment included ensuring that patients can cope with the cancer and treatment and have a QOL benefit. HCPs expressed desire for treatments with a more CC-specific mode of action and therapies that enhance QOL.Conclusions: These surveys underscore the need for increased awareness among HCPs of CC and its management.